PrEP at IAS 2017 / IAS Coverage
Safety and acceptability trial of the dapivirine vaginal ring in U.S. adolescents - Dapivirine Vaginal Ring Safe and Acceptable in US Adolescents - (08/07/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
An Open Label Multiple Dose Phase 1 Assessment of Long Acting Rilpivirine - Long-Acting Rilpivirine Suppresses Replication in Rectal Explants - Mark (08/07/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
One-year experience with Pre-Exposure Prophylaxis (PrEP) Implementation in France with TDF/FTC - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Is on-demand PrEP with TDF/FTC effective among MSM with infrequent sexual intercourse? - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Potential for HIV transmission among adolescents and young adults receiving antiretroviral therapy - 'PrEP missed opportunities' - (08/03/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Impact of microbiota on female genital tissue and plasma concentrations of dapivirine - (08/02/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Limited implementation of HIV pre-exposure prophylaxis among public health departments in North Carolina, United States - (08/02/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (08/02/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Reasons for not using PrEP in a national on-line sample of U.S. men who have sex with men (MSM) - Cost, Side Effects, Access Lead Reasons for PrEP Nonuse by US MSM  - (07/31/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Experiences and perceptions of PrEP among gay, MSM, and TGW in the PROUD study in England: 'Rules' of Sex, Psychological, Psychosocial Benefits -  (07/31/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Adherence intentions, long-term adherence and HIV acquisition among PrEP users in the PROUD open-label randomised control trial of PrEP in England - (07/31/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Long term follow up of PROUD Evidence for high continued HIV exposure and durable effectiveness of PrEP - (07/31/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Is on-demand PrEP a suitable tool for MSM who practice chemsex? Results from a sub-study of the ANRS-IPERGAY trial - Chemsex Users in IPERGAY Twice as Likely to Use As-Needed PrEP -  (07/28/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus -  (07/27/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Impact of risk perception trajectory on PrEP and condom use among Men who have Sex with Men during the Open-Label-Extension of the ANRS-IPERGAY trial - (07/27/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Single Doses as Low as 0.5 mg of the Novel NRTTI MK-8591 Suppress HIV for At Least Seven Days - (07/26/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17) 
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17)
IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
A Single Monotherapy Dose of MK-8591,a Novel NRTI, Suppresses HIV for Ten Days - (02/24/16)
Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA
Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis - (02/24/16)
Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA
   
News Updates

HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya

Trials. 2019 Jul 4;20(1):396. doi: 10.1186/s13063-019-3521-2.

HIV eliminated from the genomes of living animals

Nature Communications | June 2019

Genotype Testing at HIV Diagnosis Provides No Benefit 

Infectious Disease Advisor | June 24, 2019

Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection

Science Translational Medicine | June 15, 2019

AIDSinfo Updates Investigational HIV Drug Fact Sheets

AIDSinfo | June 14, 2019

Women and Clinical Trials

The New York Times | June 14, 2019

GSK partners with CRISPR pioneer Doudna to search for new drugs

STAT News | June 13, 2019

Durable Control of HIV Infection in the Absence of Antiretroviral Therapy - Opportunities and Obstacles

Viewpoint | June 6, 2019

Trump administration imposes new restrictions on fetal tissue research

Washington Post | June 5, 2019

Statement from the Department of Health and Human Services

HHS.gov | June 5, 2019

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

JAMA Oncol. Published online June 2, 2019

HIV Vaccine Awareness Day 2019 — May 18, 2019

National Institutes of Health | May 17, 2019

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from ...

Yahoo Finance | May 13, 2019

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens - LATITUDE study compares monthly injectable antiretroviral therapy to daily oral drugs

NIH | May 9, 2019

NIH awards will advance development of vaccines for sexually transmitted infections

NIH | May 5, 2019

Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base

Cancer. 2019 May 3. doi: 10.1002/cncr.32158

Boston hospital receives largest philanthropic gift in history for HIV/AIDS vaccine research

WCVB Boston | April 25, 2019

Novel antibody may suppress HIV for up to four months

NIH | April 17, 2019

Scientists find another way HIV can hide from vaccines

Yale News | April 10, 2019

Orion Biotechnology to Present OB-002 in Vitro Potency Data at the 10th International AIDS Society HIV Science Meeting in Mexico City in July 2019

PR Newswire | March 28, 2019

Aaron Diamond AIDS Research Center to Join Columbia University

Columbia University | March 20, 2019

Curing HIV just got more complicated. Can CRISPR help?

Science Magazine | March 15, 2019

Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach

PLoS Med. 2019 Mar 4;16(3):e1002756. doi: 10.1371/journal.pmed.1002756. eCollection 2019 Mar.

This is Not A Cure for My H.I.V.

New York Times | March 9, 2019

One step closer to ultra-long-acting PREP?

AIDS: march 2019

New Target for HIV Immune Therapy and Cure to be Explored by Trans-Atlantic Industry-Academia Collaboration

NATAP | February 20th, 2019

Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge

Nat Commun. 2019 Feb 18;10(1):798. doi: 10.1038/s41467-019-08739-4

NIH Clinical Trial to Track Outcomes of Liver Transplantation from HIV-Positive Donors to HIV-Positive Recipients

HIV.gov | February 15, 2019

Ending the HIV Epidemic: A Plan for the United States

NIH | February 7, 2019

Study of PrEP and vaginal ring for HIV prevention begins in girls and young women

NIH | February 7, 2019

HIV-AIDS drug could help treat Alzheimer's and other age-related diseases, Brown researchers say

The Providence Journal | February 6, 2019

Hodgkin's lymphoma and its association with EBV and HIV infection

Crit Rev Clin Lab Sci. 2018 Mar;55(2):102-114. doi: 10.1080/10408363.2017.1422692. Epub 2018 Jan 9

Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer

A Systematic Review

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation

BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793.

Heterosexual oral and anal sex in Kinshasa (D.R.Congo): Data from OKAPI prospective cohort

PLoS One. 2019 Jan 16;14(1):e0210398. doi: 10.1371/journal.pone.0210398. eCollection 2019

Incidence and Correlates of STIs among Black Men who have Sex with Men Participating in the HPTN 073 PrEP Study.

Clin Infect Dis. 2019 Jan 7. doi: 10.1093/cid/ciy1141.

Scientists achieve the first proof of concept for an HIV broadly-neutralising antibody vaccine in ...

aidsmap | January 2, 2019

Potential of HIV-Protective Drugs Administered Via Rectal Douches

Infectious Disease Advisor | December 26, 2018

AIDS -- an approach for targeting HIV reservoirs

Eurek Alert | December 20, 2018

AIDS: An approach for targeting HIV reservoirs

Science Daily | December 20, 2018

Study Determines Why Patients With HIV Have Higher Rates of Cancer

AJMC.com Managed Markets Network | December 14, 2018

NIH to fund HIV care and prevention research in the South

Healio | December 14, 2018

Removable PrEP implant produces high drug levels in rabbits; further studies planned

aidsmap | November 15, 2018

Johns Hopkins researchers examine testosterone use to increase BMD in HIV-infected men

EurekAlert | December 12, 2018

A protein complex from human milk enhances the activity of antibiotics and drugs against Mycobacterium tuberculosis

Antimicrob Agents Chemother. 2018 Nov 12. pii: AAC.01846-18. doi: 10.1128/AAC.01846-18

With HIV/AIDS Research Threatened, NIH Looks For Stem-Cell Alternatives

Rolling Stone | December 11, 2018

Uganda starts tests for long acting injectable ARVs

New Vision | November 9, 2018

Dapivirine and Contraceptive Levels in Dual-Purpose Vaginal Ring: 14-Day Study

HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid

Tenofovir Rectal Douche Provides Protective Drug Levels in MSM Colon Tissue - on-demand, behaviorally-congruent

HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid

Subcutaneous TAF Implants Pass 63-Day Test in Rabbits for Long-Acting PrEP

HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid

High MSM Interest in Long-Acting PrEP Regardless of Current Oral PrEP Use

HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid

The Miami monkey cured with two antibodies

aidsmap | Oct 26, 2018

The long tail of injectable PrEP is especially long for women

aidsmap | Oct 25, 2018